In a systematic review and meta-analysis, researchers evaluated whether online pain management programs are effective in the setting of chronic pain.
Fast-Act Rheuma Capsule, New Fast-Act Rheumatism Capsule, and UA-Block contain active hidden drug ingredients not listed on the product label.
Only the 60mg dose of Qulipta is indicated for the preventive treatment of chronic migraine.
New instrument, the Pain-related OUD Exacerbation Scale, shows validity.
A warning about opioid-induced hyperalgesia has been added to the prescribing information.
Using a tetherless, adhesive fingertip sensor, the device monitors several physiological markers to detect the impairment of oxygenation due to opioid use.
Approval of the modified Opioid Analgesic REMS is expected in 2024.
Sedation weaning protocol reduces total opioid exposure in infants following cardiac surgery
Zavzpret (zavegepant) nasal spray is a calcitonin gene-related peptide (CGRP) receptor antagonist.
The product was designed using the Amphastar’s proprietary nasal delivery device.
In an ancillary analysis, researchers examined changes in self-reported migraine day frequency among adolescents who completed the full 24-week CHAMP trial.
Strong recommendation made against long-term opioid therapy, especially for younger age groups, those with substance use disorder.
Nikki Kean discusses health disparities in acute pain management in emergency departments.
A team of investigators evaluated numerous factors associated with the management of pain among residents of nursing homes with dementia.
Increased demand for ibuprofen oral suspension products due to a surge in 3 circulating viruses prompted the Agency to issue compounding guidance.
Retrospective chart review shows health disparities in acute pain management among racial/ethnic minority patients and women in an emergency department.
Frequent cannabis users may have poor response to pain control after surgery and may require more rescue medications such as opioids.
Recent FDA approvals include treatments for acute low back pain, postoperative nausea and vomiting, multiple myeloma, hemophilia B, and fibromyalgia pain.
Findings observed in women with early-stage breast cancer who were taking an aromatase inhibitor and had a score of 3 or higher on BPI-WP item.
The 2022 CDC Clinical Practice Guideline is intended to help clinicians weigh the benefits and risks of opioids and alternative pain treatments for outpatients.